Granulomatosis with polyangiitis (formerly termed Wegener's granulomatosis)
Granulomatosis with polyangiitis (GPA) is a rare form of vasculitis, formerly called Wegener's granulomatosis.
GPA is an idiopathic vasculitis of medium and small arteries, characterized by necrotizing granulomatous inflammation.
It is a rare form of necrotising vasculitis characterised by (1,2):
- pulmonary disease
- upper and lower respiratory tract lesions - affecting nose, sinuses, and lung
- focal or diffuse glomerulonephritis
This disease is generally characterized by antineutrophil cytoplasm antibodies (ANCA) - however there are rare cases with negative ANCA.
- GPA affects people at any age, with predominance of the sixth and seventh decade of life.
Other summary features include:
- disease may run a course that might vary from indolence to one of rapid progression leading to life-threatening multiorgan failure
- disease generally develops over a period of time with the mean period from onset of symptoms to diagnosis ranging from 4.7 to 15 months
- without treatment it is invariably fatal
- diagnosis of GPA is based on Criteria of the American College of Rheumatology
- standard treatment procedure is divided into two essential phases, remission induction and maintenance (1)
- remission induction is based on a combination of systemic corticosteroid and immunosuppressant therapy (3). Severe (life- or organ-threatening) disease is treated with a high-dose corticosteroid plus either cyclophosphamide or rituximab. (1)
- in maintenance induction, rituximab is recommended as first-line treatment for remission maintenance for patients with severe life-threatening and non-severe GPA patients who have achieved remission with either rituximab or cyclophosphamide. Azathioprine or methotrexate may be considered as alternatives (1)
- intravenous immunoglobulin (IVIG) may be added to remission induction therapy with rituximab or cyclophosphamide to achieve disease control while waiting for remission induction therapy to become effective. (4)
- Note - necrotising granulomatous inflammation usually involving the upper and lower respiratory tract, and necrotising vasculitis predominantly affecting small to medium vessels (e.g. capillaries, venules, arterioles, arteries and veins)
- necrotising glomerulonephritis is common
- in 80%–95% of the patients the first symptoms of GPA are otorhinolaryngological manifestations of head and neck including nose/sinuses, ears, eyes, larynx/trachea, oral cavity, and salivary glands
References:
- Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023 Mar 16:ard-2022-223764.
- McKinney EF, Willcocks LC, Broecker V, et al. The immunopathology of ANCA-associated vasculitis. Semin Immunopathol. 2014 Jul;36(4):461-78.
- Kidney Disease Improving Global Outcomes. 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Mar 2024 [internet publication]
- Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-105.
Related pages
- Epidemiology of ANCA associated vasculitis
- Aetiology and pathogenesis of ANCA associated vasculitis
- Trigger factors in ANCA associated vasculitis
- Clinical features
- Differential diagnosis of ANCA associated vasculitis
- Diagnosis
- Assessment of end organ damage in ANCA associated vasculitis
- Treatment
- Prognosis
- ANCA-associated vasculitis
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.